Latest News for: bcr

Edit

EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 12 Jun 2026
HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR..ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) ... carrying BCR..ABL1 fusion mutations or point mutations.
Edit

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR) (BCR Wealth Strategies LLC)

Public Technologies 01 May 2026
) ... The reader should not assume that the information is accurate and complete ... Washington, D.C ... BCR Wealth Strategies, LLC ... BCR Wealth Strategies LLC published this content on May 01, 2026, and is solely responsible for the information contained herein.
Edit

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML (Form 8-K) (Terns Pharmaceuticals Inc)

Public Technologies 25 Mar 2026
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR..ABL1 tyrosine ... "The first approval of a BCR..ABL1 tyrosine kinase inhibitor 25 years ago transformed the prognosis for many patients with chronic myeloid leukemia.
  • 1
×